11th Floor, Keio Fuchu 1 Chome Building
81 42 307 7480
Full Time Employees:
|Mr. Takuro Wakabayashi||Pres & Representative Director||N/A||N/A||N/A|
|Go Ito||CFO & Board Member||N/A||N/A||N/A|
|Koji Ohe||Gen. Counsel||N/A||N/A||N/A|
|Noriaki Inamura Ph.D.||Head of R&D and Board Member||N/A||N/A||N/A|
TMS Co., Ltd. engages in the research and development, manufacture, and sale of drug products, quasi-drugs, drug substances, medical devices, and medical commodities. The company is developing TMS-007, a stachybotrys microspora triprenyl phenol (SMTP) congener with prothrombolytic and anti-inflammatory/antioxidative activities, which has completed Phase 2a clinical trials for acute ischemic stroke treatment; and TMS-008, an SMTP congener with anti-inflammatory/antioxidative activities under nonclinical development for inflammatory complications, such as acute kidney injury and cancer cachexia. It is also developing TMS-009, a product candidate in preclinical development. The company was incorporated in 2005 and is headquartered in Fuchu, Japan.
TMS Co., Ltd.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.